Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).
about
Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance.Cancer stratification by molecular imaging.Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors.Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.Targeted delivery of platinum-taxane combination therapy in ovarian cancer.Molecular Imaging of Ovarian CancerAcetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell CarcinomaRole of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications.Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas.Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.Molecular imaging-its current role in cancer.Development of a New Folate-Derived Ga-68-Based PET Imaging Agent.Nuclear medicine for imaging of epithelial ovarian cancer.Small Molecules for Active Targeting in Cancer.Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.Imaging of anticancer drug action in single cells.Folate Receptor-Positive Gynecological Cancer Cells: In Vitro and In Vivo Characterization.Intracellular delivery and ultrasonic activation of folate receptor-targeted phase-change contrast agents in breast cancer cells in vitro.Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies.Targeted Delivery of Cytotoxic Drugs: Challenges, Opportunities and New Developments.Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics.Enhanced Therapeutic Activity of Non-Internalizing Small Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination With Targeted Interleukin-2.Preclinical evaluation of isostructural Tc-99m- and Re-188-folate-Gly-Gly-Cys-Glu for folate receptor-positive tumor targeting.Phase I clinical trial of 99mTc-etarfolatide, an imaging agent for folate receptor in healthy Japanese adults.Advances in targeting the folate receptor in the treatment/imaging of cancers.A bivalent small molecule-drug conjugate directed against carbonic anhydrase IX can elicit complete tumour regression in miceLeveraging PET to image folate receptor α therapy of an antibody-drug conjugate
P2860
Q30365844-C8557A46-ED0A-4650-BA04-6DA22461FCA6Q35380664-3480C0B5-141D-4856-8B54-563A10425A79Q35780797-F3C83207-7A99-46CC-BAEF-D6727FC4A148Q36093220-17827013-F1A1-40AD-BC49-52D8F0D63FC9Q36395811-67B85E79-ADC5-48E2-9614-E1B031F902C4Q37305724-7472BEC1-9833-4567-A509-7AB10D814199Q37559487-613E0A2D-50E0-4558-BB4D-B025ABEBE193Q38309549-333F53F8-19B3-4450-8DF3-F28C543724CFQ38340008-921A228B-150F-474F-8FE1-73CE4F5F1C8EQ38524502-47DF2DD1-E6C2-4CB7-9110-0AC967057EB4Q38562599-4C4FC873-F9CC-4A9F-9B76-B55DC9E3C7DEQ38716580-2A1E3B3C-131E-41E1-9B7A-1A80297515C2Q38777588-30876A65-E655-492F-9059-2EFC5528044AQ38780383-0C6B8086-4C93-4E5F-ADF5-85036E5A9EF6Q38940035-BEA4CD43-98AA-4872-B512-B2A2F90EADE9Q38995020-FB1691D6-4104-4DFE-A168-EE659A6B6D80Q39001530-EBE8B6DA-7BDF-4671-BDAD-68E6C8473D2EQ39392711-C2F0410A-C426-4531-8B08-E1B5C3A5C659Q42366884-5EB8842A-B76C-486F-A44C-0D6E7D03D2E9Q44867216-343E52FE-079E-448B-BBF9-4608EB58EDF3Q49750232-E1146C56-86CA-47ED-B570-26D4FB0F4796Q50084824-4A0B0232-6483-486A-BFD0-593A7D23DF69Q50422486-BB8A3DFD-30D6-4C2F-B859-2A6B28D15630Q52565554-EAD2F088-4E3F-4207-A3E4-7E371B9FA526Q53166641-0FBC646C-C763-4032-A271-6F0198D70CF0Q53396871-59C4AE74-38B3-4B78-B02E-235353605025Q55315165-FDD50876-7FFE-4FEE-8F90-D3447251537AQ57911942-6274515F-696A-4F62-BD76-4EF39F196755Q58699756-2C4922A3-91A0-406C-A61C-C9609EEA862E
P2860
Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Phase II study of treatment of ...... ng agent (99mTc-etarfolatide).
@en
Phase II study of treatment of ...... -receptor-targeted therapeutic
@nl
type
label
Phase II study of treatment of ...... ng agent (99mTc-etarfolatide).
@en
Phase II study of treatment of ...... -receptor-targeted therapeutic
@nl
prefLabel
Phase II study of treatment of ...... ng agent (99mTc-etarfolatide).
@en
Phase II study of treatment of ...... -receptor-targeted therapeutic
@nl
P2093
P2860
P356
P1433
P1476
Phase II study of treatment of ...... ng agent (99mTc-etarfolatide).
@en
P2093
A H Maurer
H W Strauss
J M Uszler
J T Symanowski
R N Joyrich
R T Morris
R W Naumann
P2860
P304
P356
10.1093/ANNONC/MDU024
P577
2014-04-01T00:00:00Z